SNS 032

Drug Profile

SNS 032

Alternative Names: BMS-387032; SNS-032

Latest Information Update: 29 Jun 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Sunesis Pharmaceuticals
  • Class Antineoplastics; Oxazoles; Small molecules
  • Mechanism of Action Apoptosis inhibitors; Cyclin dependent kinase 9 inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase-activating kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued B cell lymphoma; Solid tumours

Most Recent Events

  • 22 Apr 2009 Preclinical pharmacodynamics data presented at the 100th Annual Meeting of the American Association for Cancer Research (AACR-2009)
  • 31 Dec 2008 Discontinued - Phase-I for B-cell lymphoma in USA (IV)
  • 31 Dec 2008 Discontinued - Phase-I/II for Solid tumours in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top